Loading data for LGVN — first visit, this takes a few seconds.
Longeveron Inc. (LGVN)
NasdaqCM: LGVN
· Real-Time Price · USD
6.90
+0.18 (2.68%)
At close: Aug 31, 2026, 8:00 PM
6.62
-4.09%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Longeveron Inc. (LGVN) Stock Price, Analysis & Data
No data available
| Bid | 5.22 |
| Market Cap | 22M |
| Revenue (ttm) | 1.19M |
| Net Income (ttm) | -23.5M |
| -0.25 | |
| -10 | |
| n/a | |
| -4.51 | |
| P/B (ttm) | 21.04 |
| P/S (ttm) | 18.53 |
| Earnings Date | Nov 4, 2026 |
| Ask | 8.66 |
| Volume | 104,620 |
| Avg. Volume (20D) | 40,369 |
| Open | 6.75 |
| Previous Close | 6.72 |
| Day's Range | 6.51 - 7.30 |
| 52-Week Range | 4.75 - 12.30 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2021
Employees 38
Stock Exchange NasdaqCM
Ticker Symbol LGVN
Website https://longeveron.com
Financial Performance
In 2025, Longeveron's revenue was 1.2M, a decrease of -49.87% compared to the previous year's 2.39M. Earnings were -22.7M, an increase of 42.14%.
Financial StatementsEarnings Surprise
Longeveron has released their quarterly earnings on Aug 12, 2026:
- Revenue of $398K misses estimates by $0, with 4.46% YoY growth.
- EPS of -1.9 misses estimates by 0.00, with 42.42% YoY growth.
Longeveron Inc. is scheduled to release its earnings on Nov 4, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2